Cefixime
Suprax (cefixime) is a small molecule pharmaceutical. Cefixime was first approved as Suprax on 1989-04-28. It is used to treat bacterial infections, bacterial pneumonia, bacterial skin diseases, bronchitis, and escherichia coli infections amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| respiratory tract diseases | D012140 |
| otorhinolaryngologic diseases | D010038 |
| urogenital diseases | D000091642 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Suprax (generic drugs available since 2007-04-10)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| bacterial pneumonia | EFO_1001272 | D018410 | J15.9 |
| bacterial skin diseases | — | D017192 | — |
| bronchitis | — | D001991 | J40 |
| escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
| gonorrhea | DOID_7551 | D006069 | A54 |
| haemophilus infections | EFO_1001127 | D006192 | — |
| klebsiella infections | EFO_1001353 | D007710 | — |
| moraxellaceae infections | EFO_1001072 | D045828 | — |
| otitis media | EFO_0004992 | D010033 | H66.9 |
Show 5 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cefixime, Suprax, Lupin Ltd | |||
| 9233112 | 2028-12-14 | DP | U-1676 |
HCPCS
No data
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropenia | D064147 | — | 2 | 1 | 3 | — | 6 | ||
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | 2 | 1 | 3 |
| Sepsis | D018805 | A41.9 | — | — | — | 1 | 1 | 2 | |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | — | 1 | 1 | 2 |
| Leukemia | D007938 | C95 | — | — | 1 | 1 | — | 2 | |
| Peritonitis | D010538 | EFO_0008588 | K65 | — | — | — | 1 | 1 | 2 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | 1 | — | 1 |
| Aspiration pneumonia | D011015 | EFO_1001399 | J69.0 | — | — | — | 1 | — | 1 |
| Endocarditis | D004696 | EFO_0000465 | I33 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 2 | 6 | — | — | 8 |
| Neutropenia | D009503 | D70 | 1 | — | 2 | — | — | 3 | |
| Septic shock | D012772 | A48.3 | — | — | 1 | — | 1 | 2 | |
| Neoplasms | D009369 | C80 | — | 1 | 1 | — | — | 2 | |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | 2 | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | 1 | |
| Lymphoma | D008223 | C85.9 | — | — | 1 | — | — | 1 | |
| Hot flashes | D019584 | — | — | 1 | — | — | 1 | ||
| Wound infection | D014946 | — | 1 | 1 | — | — | 1 | ||
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal microbiome | D000069196 | — | 1 | — | — | — | 1 | ||
| Communicable diseases | D003141 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | — | — | — | — | 5 | ||
| Bacterial infections | D001424 | A49 | 2 | — | — | — | — | 2 | |
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
| Primary myelofibrosis | D055728 | D47.4 | 1 | — | — | — | — | 1 | |
| Multiple myeloma | D009101 | C90.0 | 1 | — | — | — | — | 1 |
Show 18 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Critical illness | D016638 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CEFIXIME |
| INN | cefixime |
| Description | Cefixime is a third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections. It has a role as an antibacterial drug and a drug allergen. |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC(=O)O)c3csc(N)n3)[C@H]2SC1 |
Identifiers
| PDB | — |
| CAS-ID | 79350-37-1 |
| RxCUI | 1546021 |
| ChEMBL ID | CHEMBL1541 |
| ChEBI ID | 472657 |
| PubChem CID | 5362065 |
| DrugBank | DB00671 |
| UNII ID | XZ7BG04GJX (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,926 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,638 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more